Advertisement

Tumor Biology

, Volume 35, Issue 9, pp 8537–8541 | Cite as

Targeting SMAD3 for inhibiting prostate cancer metastasis

  • Qing Xia
  • Chengjiang Li
  • Pingda Bian
  • Jue Wang
  • Shuai DongEmail author
Research Article

Abstract

Although SMAD3 signaling has been suggested to play a role in the metastasis of various cancers, its possible involvement as well as the underlying mechanism in the pathogenesis in prostate cancer remains unclear. Here, we found that the MMP9 level, an indicator of the invasiveness of cancer cells, negatively correlates with the activity of phosphorylated SMAD3 levels in the prostate cancer patients. Moreover, the phosphorylated SMAD3 also appeared to regulate the MMP9 level in a prostate cancer cell line, PC3. Augmented phosphorylated SMAD3 inhibited MMP9 and invasiveness of PC3 cells, while inhibition of phosphorylated SMAD3 activated MMP9 and promoted PC3 cell invasiveness. Furthermore, forced MMP9 inhibition abolished the effect of phosphorylated SMAD3 on the invasiveness of PC3 cells, while forced MMP9 activation abolished the effect of phosphorylated SMAD3 on the invasiveness of PC3 cells. Taken together, our data suggest the possibility of the existence of a unique signaling cascade in which SMAD3 signaling regulates MMP9 during cancer metastasis.

Keywords

Prostate cancer SMAD3 MMP9 

Notes

Acknowledgments

This work was financially supported by the Department of Health of Zhejiang Province (No. 201234615).

Conflict of interest

None

References

  1. 1.
    Olsson AY, Cooper CS. The molecular basis of prostate cancer. Br J Hosp Med (Lond). 2005;66:612–6.CrossRefGoogle Scholar
  2. 2.
    Powell IJ, Bollig-Fischer A. Minireview: The molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol. 2013;27:879–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. Nephro-Urol Mon. 2013;5:792–800.CrossRefGoogle Scholar
  4. 4.
    Massague J. Tgfbeta in cancer. Cell. 2008;134:215–30.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Shi Y, Massague J. Mechanisms of tgf-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700.CrossRefPubMedGoogle Scholar
  6. 6.
    Kretzschmar M, Massague J. Smads: mediators and regulators of tgf-beta signaling. Curr Opin Genet Dev. 1998;8:103–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Massague J, Chen YG. Controlling tgf-beta signaling. Genes Dev. 2000;14:627–44.PubMedGoogle Scholar
  8. 8.
    Massague J. Tgfbeta signalling in context. Nat Rev Mol Cell Biol. 2012;13:616–30.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of smad7. Proc Natl Acad Sci U S A. 2014;111:E1211–20.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Huang SQ, Liao QJ, Wang XW, Xin DQ, Chen SX, Wu QJ, et al. Rnai-mediated knockdown of pituitary tumor- transforming gene-1 (pttg1) suppresses the proliferation and invasive potential of pc3 human prostate cancer cells. Braz J Med Biol Res. 2012;45:995–1001.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Huang S, Liao Q, Li L, Xin D. Tumour Biol. 2014. doi: 10.1007/s13277-014-1818-z.PubMedCentralGoogle Scholar
  12. 12.
    Zhang J, Wang Y, Li D, Jing S. Notch and tgf-beta/smad3 pathways are involved in the interaction between cancer cells and cancer-associated fibroblasts in papillary thyroid carcinoma. Tumour Biol. 2014;35:379–85.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Qing Xia
    • 1
  • Chengjiang Li
    • 1
  • Pingda Bian
    • 2
  • Jue Wang
    • 2
  • Shuai Dong
    • 1
    Email author
  1. 1.Department of Endocrinology and Surgery, The First Affiliated Hospital, Medical CollegeZheJiang UniversityHangZhouChina
  2. 2.Department of Geriatrics, Zhejiang Province People’s HospitalMedical CollegeHangZhouChina

Personalised recommendations